This page shows the latest Juventas news and features for those working in and with pharma, biotech and healthcare.
This includes a deal made in 2018, when Astellas bought out gene therapy biotech Juventas for an exclusive option on its non-viral gene therapy JVS-100.
Targeting faecal incontinence, which affects 50m worldwide. Astellas has made another deal in the gene therapy category, licensing a candidate for treating faecal incontinence from US biotech Juventas Therapeutics. ... Juventas has previously shown that
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Among these, Juventas Therapeutics' non-viral gene therapy JVS-100 - which expresses stromal cell-derived factor-1 (SDF-1) and activates the body's own tissue repair pathways - has been
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...